

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities, nor is it intended to invite any such offer or invitation. This announcement or any copy thereof may not be directly or indirectly brought into or distributed in the United States (including its territories and possessions, any state of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell any securities or a solicitation of an offer to purchase or subscribe for any securities in the United States or elsewhere. Securities may not be offered or sold in the United States unless registered or exempted from registration under the United States Securities Act of 1933, as amended. Any public offering of securities in the United States will be made only by means of a prospectus, which may be obtained from the issuer or the seller of the securities and contains detailed information about the issuer and its management as well as financial information. The Company does not intend to make a public offering of the securities referred to in this announcement in the United States.



TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2617)

**COMPLETION OF PLACING OF NEW H SHARES
UNDER THE GENERAL MANDATE**

Sole Overall Coordinator and Sole Placing Agent



Reference is made to the announcement of TransThera Sciences (Nanjing), Inc. (the “**Company**”) dated April 15, 2026 (the “**Announcement**”) in relation to the Placing. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

COMPLETION OF THE PLACING

The Company is pleased to announce that all the conditions set out in the Placing Agreement had been fulfilled and Completion took place on April 21, 2026. An aggregate of 5,085,000 Placing Shares have been successfully placed by the Placing Agent at the Placing Price of HK\$57.03 per Placing Share to not less than six Placees.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, the Placees are professional, institutional or other investors who and whose respective ultimate beneficial owners are Independent Third Parties. None of the Placees has become a substantial shareholder (as defined under the Listing Rules) of the Company immediately upon Completion.

The 5,085,000 Placing Shares represent approximately 1.67 % of the number of existing issued H Shares and approximately 1.27 % of the number of existing issued Shares of the Company immediately prior to Completion, and approximately 1.65 % of the number of issued H Shares and approximately 1.26 % of the number of issued Shares of the Company as enlarged by the allotment and issue of the Placing Shares.

USE OF PROCEEDS

The gross proceeds from the Placing amounted to approximately HK\$290.00 million and the net proceeds from the Placing (after deducting the Placing commission and other relevant costs and expenses of the Placing) amounted to approximately HK\$282.15 million. On such basis, the net issue price was approximately HK\$55.49 per Placing Share.

The Company intends to allocate the net proceeds of the Placing (after deduction of expenses for issuance) as follows:

- (i) approximately 57% of the net proceeds of the Placing, or approximately HK\$160.83 million for the research and development, including the clinical development of our Core Product, Tinengotinib covering indication such as advanced stage breast cancer, hepatocellular carcinoma, castration-resistant prostate cancer, and the clinical development of TT-00973;
- (ii) approximately 33% of the net proceeds of the Placing, or approximately HK\$93.11 million for the manufacturing of our Core Product, Tinengotinib in the PRC, as well as its commercialization, including the build-out of commercial teams and related marketing activities; and
- (iii) approximately 10% of the net proceeds of the Placing, or approximately HK\$28.21 million for working capital and general corporate purposes.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE COMPLETION OF THE PLACING

The table below sets out a summary of the shareholding structure of the Company (i) immediately before the Completion; and (ii) immediately upon the Completion:

Class of Shares	Immediately before the Completion		Immediately upon the Completion	
	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾	Number of issued Shares	Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾
Unlisted Shares				
Core connected persons ⁽²⁾	50,259,832	12.60%	50,259,832	12.44%
Other unlisted shareholders	44,971,128	11.27%	44,971,128	11.13%
Total number of Unlisted Shares	95,230,960	23.87%	95,230,960	23.57%
H Shares				
Core connected persons ⁽²⁾	80,597,797	20.20%	80,597,797	19.94%
Placees	—	—	5,085,000	1.26%
Other H shareholders	223,168,876	55.93%	223,168,876	55.23%
Total number of H Shares	303,766,673	76.13%	308,851,673	76.43%
Total	398,997,633	100.00%	404,082,633	100.00%

Notes:

- (1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- (2) Including the 47,847,024 H Shares held by Dr. Frank WU (吳永謙) as beneficial owner, as well as his interest in Shares held by 32,750,773 H Shares and 50,259,832 Unlisted Shares through controlled corporations.

By order of the Board
TransThera Sciences (Nanjing), Inc.
(藥捷安康(南京)科技股份有限公司)
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, April 21, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Mr. Li Shu Pai, Ms. Chui Hoi Yam and Ms. Zheng Zhelan as independent non-executive directors.